PLRX Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. (PLRX) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.9% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Pliant Therapeutics, Inc.
Pliant Therapeutics Inc. is a late-stage biopharmaceutical company which involved in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. The company's lead product candidate includes bexotegrast. Pliant Therapeutics Inc., formerly known as PLANT THERAPEUT, is based in SOUTH SAN FRANCISCO, Calif.
Sector
Healthcare
Industry
Biotechnology